

Special Issue

Novel Vaccine Approaches for Emerging RNA Viruses

Message from the Guest Editor

Emerging RNA viruses continue to pose a unique threat to global human health. This special issue seeks manuscripts that evaluate new approaches to develop vaccine technology in the field of emerging RNA viruses. These approaches can include basic proof-of-concept approaches for vaccine development, novel adjuvant approaches, immunology of vaccine approaches, and translational efforts to evaluate immunogenicity and efficacy of a vaccine approach for emerging RNA viruses. We are particularly interested in manuscripts that evaluate novel platforms for rapid vaccine development. A continued and persistent effort to develop novel vaccine candidates and approaches for a variety of RNA viruses will provide an important pipeline of data as new RNA viruses emerge and threaten global human health in the future.

Guest Editor

Dr. David Beckham

Division of Infectious Diseases, Departments of Medicine and Immunology & Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA

Deadline for manuscript submissions

closed (31 May 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/63142

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).